Neurotech International (ASX:NTI) has announced positive results from its first-in-human pharmacokinetic study evaluating NTI164, a proprietary CBDA-rich, standardised formulation of cannabinoids. …
Latest Video
New Stories
-
Health department admits review of blood arrangements considering defunding products
June 3, 2025 - - Latest News -
New data uncovers our most painful moments as access to treatment expands
June 2, 2025 - - Latest News -
Australian innovation could revolutionise the early detection of ovarian cancer
June 2, 2025 - - Latest News -
AusBiotech welcomes shadow ministry and encourages bipartisan support for life sciences sector
June 2, 2025 - - Latest News -
Radiopharm Theranostics reports Preclinical Lu177-B7H3-mAb data
June 2, 2025 - - Australian Biotech -
Neurotech announces positive human PK study results for NTI164
June 2, 2025 - - Australian Biotech -
Cardiex receives TGA approval for CONNEQT Pulse arterial health monitor
June 2, 2025 - - Australian Biotech